CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making

Worst, Thomas S. and Weis, Cleo-Aron and Stoehr, Robert and Bertz, Simone and Eckstein, Markus and Otto, Wolfgang and Breyer, Johannes and Hartmann, Arndt and Bolenz, Christian and Wirtz, Ralph M. and Erben, Philipp (2018) CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. SCIENTIFIC REPORTS, 8: 14383. ISSN 2045-2322,

Full text not available from this repository. (Request a copy)

Abstract

Deletions of the cell cycle control gene CDKN2A are described as progression markers of non-muscle invasive bladder cancer and to be associated with fibroblast growth factor 3 (FGFR3) mutations. The prognostic role of CDKN2A RNA expression in muscle invasive bladder cancer (MIBC) is under discussion. In 80 MIBC patients (m/f60/20) who underwent radical cystectomy the expression of CDKN2A and FGFR3 was examined with qRT-PCR (test cohort). The MDA cohort (n = 57) and the TCGA cohort (n = 365) served for validation. The expression of drug target genes and TCGA molecular subtypes was correlated with CDKN2A expression. In the test cohort CDKN2A(high) patients (n = 8; 10.0%) had a significantly shorter recurrence-free (p = 0.018) and disease-specific (p = 0.006) survival compared to the rest of the cohort. A similar stratification was seen in the validation cohorts (CDKN2A(high): n = 7, 12.3%, p = 0.001; n = 46, 12.6%, p = 0.011). In the TCGA cohort these patients had a comparably low expression of drug target genes. The expression of CDKN2A significantly differed among TGCA molecular subtypes. 71.7% of CDKN2A(high) were TCGA basal squamous tumours but also show divergent molecular features compared to this group. In summary CDKN2A RNA expression-based risk stratification of MIBC allows the identification of a CDKN2A(high) poor prognosis group with low expression of drug target genes.

Item Type: Article
Uncontrolled Keywords: COMPREHENSIVE MOLECULAR CHARACTERIZATION; FREQUENT GENETIC ALTERATIONS; UROTHELIAL CARCINOMA; P16 EXPRESSION; FGFR3; P53; PAZOPANIB; SUBTYPES; CLASSIFICATION; IDENTIFICATION;
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Urologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 12 Dec 2019 12:41
Last Modified: 12 Dec 2019 12:41
URI: https://pred.uni-regensburg.de/id/eprint/13828

Actions (login required)

View Item View Item